Download PDF
Aktuelle Rheumatologie 2015; 40(02): 124-131
DOI: 10.1055/s-0034-1398670
Übersichtsarbeit
© © Georg Thieme Verlag KG Stuttgart · New York

Die Rolle von IL-1β in der Dermatologie*

The Role of IL-1β in Dermatology
R. U. Reidel
1   Klinik für Dermatologie und Allergologie, Charité – Universitätsmedizin Berlin
,
C. E. Zielinski
1   Klinik für Dermatologie und Allergologie, Charité – Universitätsmedizin Berlin
2   Berlin-Brandenburger Centrum für Regenerative Therapien (BCRT), Charité – Universitätsmedizin Berlin
3   Institut für Medizinische Mikrobiologie, Immunologie und Hygiene, Technische Universität München
› Author Affiliations
Further Information

Publication History

Publication Date:
14 April 2015 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Zytokine sind maßgeblich an der Modulation von Immunantworten beteiligt und tragen so entscheidend zur Pathogenese vieler chronisch inflammatorischer Dermatosen bei. Interleukin-1beta (IL-1β) ist das älteste Zytokin und genießt auch viele Jahre nach seiner initialen Entdeckung 1977 sehr große wissenschaftliche und klinische Aufmerksamkeit. Nach der Entdeckung des Inflammasomenkomplexes, der Multiprotein-Maschinerie, die zur Sekretion von bioaktivem IL-1β führt, explodierte die wissenschaftliche Aktivität an diesem Molekül und führte auch zu neuen Immuntherapien im Bereich der autoinflammatorischen Syndrome, die durch Mutationen im Inflammasom und gesteigerte IL-1β-Aktivität gekennzeichnet sind. In dem vorliegenden Übersichtsartikel soll aufgezeigt werden, dass das Spektrum IL-1β-vermittelter Hauterkrankungen die autoinflammatorischen Syndrome weit übersteigt und dass diese Erkrankungen aufgrund ihrer IL-1β-vermittelten Pathogenese bei Versagen konventioneller Therapien ebenfalls von IL-1β-spezifischen Immuntherapien profitieren dürften.

Abstract

Cytokines are crucial for immunomodulation and are involved in the pathogenesis of multiple chronic inflammatory skin diseases. IL-1β is the oldest cytokine but still enjoys a lot of scientific and clinical attention despite its initial identification in 1977. After the discovery of the inflammasome, a multiprotein machinery, which leads to the secretion of bioactive IL-1β, research on this molecule has increased significantly and led to new immunotherapies for autoinflammatory syndromes, which are characterized by mutations in the inflammasome and increased IL-1β activity. In this review article we would like to highlight that the spectrum of IL-1β mediated skin diseases goes far beyond autoinflammatory syndromes. Therefore, several other chronic inflammatory skin diseases that fail to respond to conventional therapies could profit from IL-1β targeting strategies due to the involvement of IL-1β in their pathogenesis.

Schlüsselwörter

Inflammasom - IL-1b - Dermatosen

Key words

inflammasome - IL-1b - skin diseases
 

  • Literatur

  • 1 Dinarello CA, Renfer L, Wolff SM. Human leukocytic pyrogen: purification and development of a radioimmunoassay. Proc Natl Acad Sci USA 1977; 74: 4624-4627
    CrossrefPubMedGoogle Scholar
  • 2 Martinon F, Burns K, Tschopp J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell 2002; 10: 417-426
    CrossrefPubMedGoogle Scholar
  • 3 Feldmeyer L, Keller M, Niklaus G et al. The inflammasome mediates UVB-induced activation and secretion of interleukin-1beta by keratinocytes. Curr Biol 2007; 17: 1140-1145
    CrossrefPubMedGoogle Scholar
  • 4 Zielinski CE, Zuberbier T, Maurer M. Immunoregulation in cutaneous allergy: prevention and control. Curr Opin Allergy Clin Immunol 2012; 12: 498-503
    CrossrefPubMedGoogle Scholar
  • 5 Dombrowski Y, Peric M, Koglin S et al. Cytosolic DNA triggers inflammasome activation in keratinocytes in psoriatic lesions. Sci Transl Med 2011; 3: 82ra38
    CrossrefPubMedGoogle Scholar
  • 6 Zielinski CE, Mele F, Aschenbrenner D et al. Pathogen-induced human TH17 cells produce IFN-gamma or IL-10 and are regulated by IL-1beta. Nature 2012; 484: 514-518
    CrossrefPubMedGoogle Scholar
  • 7 Asadullah K, Sabat R, Friedrich M et al. Interleukin-10: an important immunoregulatory cytokine with major impact on psoriasis. Curr Drug Targets Inflamm Allergy 2004; 3: 185-192
    CrossrefPubMedGoogle Scholar
  • 8 Lowes MA, Kikuchi T, Fuentes-Duculan J et al. Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J Invest Dermatol 2008; 128: 1207-1211
    CrossrefPubMedGoogle Scholar
  • 9 Ben-Sasson SZ, Hu-Li J, Quiel J et al. IL-1 acts directly on CD4 T cells to enhance their antigen-driven expansion and differentiation. Proc Natl Acad Sci USA 2009; 106: 7119-7124
    CrossrefPubMedGoogle Scholar
  • 10 Sallusto F, Zielinski CE, Lanzavecchia A. Human Th17 subsets. Eur J Immunol 2012; 42: 2215-2220
    CrossrefPubMedGoogle Scholar
  • 11 Larsen CM, Faulenbach M, Vaag A et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 2007; 356: 1517-1526
    CrossrefPubMedGoogle Scholar
  • 12 Okamura H, Tsutsi H, Komatsu T et al. Cloning of a new cytokine that induces IFN-gamma production by T cells. Nature 1995; 378: 88-91
    CrossrefPubMedGoogle Scholar
  • 13 Dinarello CA. Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol 2009; 27: 519-550
    CrossrefPubMedGoogle Scholar
  • 14 McDermott MF, Aksentijevich I, Galon J et al. Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. Cell 1999; 97: 133-144
    CrossrefPubMedGoogle Scholar
  • 15 Loock J, Lamprecht P, Timmann C et al. Genetic predisposition (NLRP3 V198M mutation) for IL-1-mediated inflammation in a patient with Schnitzler syndrome. J Allergy Clin Immunol 2010; 125: 500-502
    CrossrefPubMedGoogle Scholar
  • 16 Pizzirani C, Falzoni S, Govoni M et al. Dysfunctional inflammasome in Schnitzler’s syndrome. Rheumatology (Oxford) 2009; 48: 1304-1308
    CrossrefPubMedGoogle Scholar
  • 17 Volz T, Wolbing F, Fischer J et al. Dermal interleukin-1 expression and effective and long-lasting therapy with interleukin-1 receptor antagonist anakinra in Schnitzler syndrome. Acta Derm Venereol 2012; 92: 393-394
    CrossrefPubMedGoogle Scholar
  • 18 Schuster C, Kranke B, Aberer E et al. Schnitzler syndrome: response to anakinra in two cases and a review of the literature. Int J Dermatol 2009; 48: 1190-1194
    CrossrefPubMedGoogle Scholar
  • 19 de Koning HD, Schalkwijk J, van der Ven-Jongekrijg J et al. Sustained efficacy of the monoclonal anti-interleukin-1 beta antibody canakinumab in a 9-month trial in Schnitzler’s syndrome. Ann Rheum Dis 2013; 72: 1634-1638
    CrossrefPubMedGoogle Scholar
  • 20 Krause K, Weller K, Stefaniak R et al. Efficacy and safety of the interleukin-1 antagonist rilonacept in Schnitzler syndrome: an open-label study. Allergy 2012; 67: 943-950
    CrossrefPubMedGoogle Scholar
  • 21 Sweet RD. An Acute Febrile Neutrophilic Dermatosis. Br J Dermatol 1964; 76: 349-356
    CrossrefPubMedGoogle Scholar
  • 22 Uhara H, Saida T, Nakazawa H et al. Neutrophilic dermatoses with acute myeloid leukemia associated with an increase of serum colonystimulating factor. J Am Acad Dermatol 2008; 59: S10-S12
    CrossrefPubMedGoogle Scholar
  • 23 White JM, Mufti GJ, Salisbury JR et al. Cutaneous manifestations of granulocyte colony-stimulating factor. Clin Exp Dermatol 2006; 31: 206-207
    CrossrefPubMedGoogle Scholar
  • 24 Codarri L, Gyulveszi G, Tosevski V et al. RORgammat drives production of the cytokine GM-CSF in helper T cells, which is essential for the effector phase of autoimmune neuroinflammation. Nat Immunol 2011; 12: 560-567
    CrossrefPubMedGoogle Scholar
  • 25 Bourke JF, Jones JL, Fletcher A et al. An immunohistochemical study of the dermal infiltrate and epidermal staining for interleukin 1 in 12 cases of Sweet’s syndrome. Br J Dermatol 1996; 134: 705-709
    CrossrefPubMedGoogle Scholar
  • 26 Delluc A, Limal N, Puechal X et al. Efficacy of anakinra, an IL1 receptor antagonist, in refractory Sweet syndrome. Ann Rheum Dis 2008; 67: 278-279
    CrossrefPubMedGoogle Scholar
  • 27 Kluger N, Gil-Bistes D, Guillot B et al. Efficacy of anti-interleukin-1 receptor antagonist anakinra (Kineret(R)) in a case of refractory Sweet’s syndrome. Dermatology 2011; 222: 123-127
    CrossrefPubMedGoogle Scholar
  • 28 Besbas N, Saatci U, Ruacan S et al. The role of cytokines in Henoch Schonlein purpura. Scand J Rheumatol 1997; 26: 456-460
    CrossrefPubMedGoogle Scholar
  • 29 Botsios C, Sfriso P, Punzi L et al. Non-complementaemic urticarial vasculitis: successful treatment with the IL-1 receptor antagonist, anakinra. Scand J Rheumatol 2007; 36: 236-237
    CrossrefPubMedGoogle Scholar
  • 30 Krause K, Mahamed A, Weller K et al. Efficacy and safety of canakinumab in urticarial vasculitis: an open-label study. J Allergy Clin Immunol 2013; 132: 751-754 e755
    CrossrefPubMedGoogle Scholar
  • 31 Nesterovitch AB, Hoffman MD, Simon M et al. Mutations in the PSTPIP1 gene and aberrant splicing variants in patients with pyoderma gangrenosum. Clin Exp Dermatol 2011; 36: 889-895
    CrossrefPubMedGoogle Scholar
  • 32 Brenner M, Ruzicka T, Plewig G et al. Targeted treatment of pyoderma gangrenosum in PAPA (pyogenic arthritis, pyoderma gangrenosum and acne) syndrome with the recombinant human interleukin-1 receptor antagonist anakinra. Br J Dermatol 2009; 161: 1199-1201
    CrossrefPubMedGoogle Scholar
  • 33 van der Zee HH, de Ruiter L, van den Broecke DG et al. Elevated levels of tumour necrosis factor (TNF)-alpha, interleukin (IL)-1beta and IL-10 in hidradenitis suppurativa skin: a rationale for targeting TNF-alpha and IL-1beta. Br J Dermatol 2011; 164: 1292-1298
    CrossrefPubMedGoogle Scholar
  • 34 Grant A, Gonzalez T, Montgomery MO et al. Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a randomized, double-blind, placebo-controlled crossover trial. J Am Acad Dermatol 2010; 62: 205-217
    CrossrefPubMedGoogle Scholar
  • 35 Amano M, Grant A, Kerdel FA. A prospective open-label clinical trial of adalimumab for the treatment of hidradenitis suppurativa. Int J Dermatol 2010; 49: 950-955
    CrossrefPubMedGoogle Scholar
  • 36 Leslie KS, Tripathi SV, Nguyen TV et al. An open-label study of anakinra for the treatment of moderate to severe hidradenitis suppurativa. J Am Acad Dermatol 2014; 70: 243-251
    CrossrefPubMedGoogle Scholar
  • 37 Coskun M, Bacanli A, Sallakci N et al. Specific interleukin-1 gene polymorphisms in Turkish patients with Behcet’s disease. Exp Dermatol 2005; 14: 124-129
    CrossrefPubMedGoogle Scholar
  • 38 Direskeneli H. Behcet’s disease: infectious aetiology, new autoantigens, and HLA-B51. Ann Rheum Dis 2001; 60: 996-1002
    CrossrefPubMedGoogle Scholar
  • 39 Bilginer Y, Ayaz NA, Ozen S. Anti-IL-1 treatment for secondary amyloidosis in an adolescent with FMF and Behcet’s disease. Clin Rheumatol 2010; 29: 209-210
    CrossrefPubMedGoogle Scholar
  • 40 Gul A, Tugal-Tutkun I, Dinarello CA et al. Interleukin-1beta-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behcet’s disease: an open-label pilot study. Ann Rheum Dis 2012; 71: 563-566
    CrossrefPubMedGoogle Scholar
  • 41 Resende RG, Abreu MH, de Souza LN et al. Association between IL1B (+3954) polymorphisms and IL-1beta levels in blood and saliva, together with acute graft-versus-host disease. J Interferon Cytokine Res 2013; 33: 392-397
    CrossrefPubMedGoogle Scholar
  • 42 Jankovic D, Ganesan J, Bscheider M et al. The Nlrp3 inflammasome regulates acute graft-versus-host disease. J Exp Med 2013; 210: 1899-1910
    CrossrefPubMedGoogle Scholar
  • 43 Birol A, Kisa U, Kurtipek GS et al. Increased tumor necrosis factor alpha (TNF-alpha) and interleukin 1 alpha (IL1-alpha) levels in the lesional skin of patients with nonsegmental vitiligo. Int J Dermatol 2006; 45: 992-993
    CrossrefPubMedGoogle Scholar
  • 44 Kotobuki Y, Tanemura A, Yang L et al. Dysregulation of melanocyte function by Th17-related cytokines: significance of Th17 cell infiltration in autoimmune vitiligo vulgaris. Pigment Cell Melanoma Res 2012; 25: 219-230
    CrossrefPubMedGoogle Scholar
  • 45 Alghamdi KM, Khurrum H, Taieb A et al. Treatment of generalized vitiligo with anti-TNF-alpha Agents. J Drugs Dermatol 2012; 11: 534-539
    PubMedGoogle Scholar
  • 46 Enk AH, Katz SI. Early molecular events in the induction phase of contact sensitivity. Proc Natl Acad Sci USA 1992; 89: 1398-1402
    CrossrefPubMedGoogle Scholar
  • 47 Watanabe H, Gaide O, Petrilli V et al. Activation of the IL-1beta-processing inflammasome is involved in contact hypersensitivity. J Invest Dermatol 2007; 127: 1956-1963
    CrossrefPubMedGoogle Scholar
  • 48 Kish DD, Gorbachev AV, Fairchild RL. IL-1 receptor signaling is required at multiple stages of sensitization and elicitation of the contact hypersensitivity response. J Immunol 2012; 188: 1761-1771
    CrossrefPubMedGoogle Scholar
  • 49 Kondo S, Pastore S, Fujisawa H et al. Interleukin-1 receptor antagonist suppresses contact hypersensitivity. J Invest Dermatol 1995; 105: 334-338
    CrossrefPubMedGoogle Scholar
  • 50 Dai X, Sayama K, Tohyama M et al. Mite allergen is a danger signal for the skin via activation of inflammasome in keratinocytes. J Allergy Clin Immunol 2011; 127: 806-814 e801–e804
    CrossrefPubMedGoogle Scholar
  • 51 Munoz-Planillo R, Franchi L, Miller LS et al. A critical role for hemolysins and bacterial lipoproteins in Staphylococcus aureus-induced activation of the Nlrp3 inflammasome. J Immunol 2009; 183: 3942-3948
    CrossrefPubMedGoogle Scholar
  • 52 Jakob T, Neuber K, Ring J. Decreased monocyte interleukin-1 beta production in atopic eczema. Br J Dermatol 1995; 132: 384-390
    CrossrefPubMedGoogle Scholar
  • 53 Renne J, Schafer V, Werfel T et al. Interleukin-1 from epithelial cells fosters T cell-dependent skin inflammation. Br J Dermatol 2010; 162: 1198-1205
    CrossrefPubMedGoogle Scholar
  • 54 Muhr P, Zeitvogel J, Heitland I et al. Expression of interleukin (IL)-1 family members upon stimulation with IL-17 differs in keratinocytes derived from patients with psoriasis and healthy donors. Br J Dermatol 2011; 165: 189-193
    CrossrefPubMedGoogle Scholar
  • 55 Johansen C, Moeller K, Kragballe K et al. The activity of caspase-1 is increased in lesional psoriatic epidermis. J Invest Dermatol 2007; 127: 2857-2864
    CrossrefPubMedGoogle Scholar
  • 56 Buerger C, Richter B, Woth K et al. Interleukin-1beta interferes with epidermal homeostasis through induction of insulin resistance: implications for psoriasis pathogenesis. J Invest Dermatol 2012; 132: 2206-2214
    CrossrefPubMedGoogle Scholar
  • 57 Bebes A, Kovacs-Solyom F, Prihoda J et al. Interleukin-1 receptors are differentially expressed in normal and psoriatic T cells. Mediators Inflamm 2014; 2014 epub
    PubMedGoogle Scholar
  • 58 Tarlow JK, Cork MJ, Clay FE et al. Association between interleukin-1 receptor antagonist (IL-1ra) gene polymorphism and early and lateonset psoriasis. Br J Dermatol 1997; 136: 147-148
    PubMedGoogle Scholar
  • 59 Tamilselvi E, Haripriya D, Hemamalini M et al. Association of disease severity with IL-1 levels in methotrexate-treated psoriasis patients. Scand J Immunol 2013; 78: 545-553
    CrossrefPubMedGoogle Scholar
  • 60 Kingsbury SR, Conaghan PG, McDermott MF. The role of the NLRP3 inflammasome in gout. J. Inflamm Res 2011; 4: 39-49
    PubMedGoogle Scholar
  • 61 McGettrick AF, O’Neill LA. NLRP3 and IL-1beta in macrophages as critical regulators of metabolic diseases. Diabetes Obes Metab 2013; 15: 19-25
    CrossrefPubMedGoogle Scholar
  • 62 So A, De Smedt T, Revaz S et al. A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther 2007; 9: R28
    CrossrefPubMedGoogle Scholar
  • 63 Kary S, Burmester GR. Anakinra: the first interleukin-1 inhibitor in the treatment of rheumatoid arthritis. Int J Clin Pract 2003; 57: 231-234
    PubMedGoogle Scholar